LivaNova (NASDAQ:LIVN) Issues FY24 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $3.05-3.15 for the period, compared to the consensus estimate of $3.00. LivaNova also updated its FY 2024 guidance to 3.050-3.150 EPS.

LivaNova Stock Up 2.0 %

Shares of LivaNova stock traded up $1.23 on Friday, reaching $64.15. The stock had a trading volume of 891,504 shares, compared to its average volume of 781,875. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.36. The company has a 50 day moving average price of $54.57 and a 200 day moving average price of $50.94. The company has a quick ratio of 2.51, a current ratio of 3.17 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The business had revenue of $294.90 million for the quarter, compared to analyst estimates of $278.17 million. During the same period in the previous year, the company earned $0.43 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. As a group, equities research analysts forecast that LivaNova will post 3.01 EPS for the current year.

Analyst Ratings Changes

LIVN has been the subject of several recent analyst reports. Barclays raised their price target on LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a report on Monday, February 26th. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research report on Thursday, April 25th. Robert W. Baird upped their price target on shares of LivaNova from $58.00 to $66.00 and gave the company a neutral rating in a research note on Thursday. Needham & Company LLC reiterated a buy rating and set a $72.00 price objective on shares of LivaNova in a research note on Wednesday. Finally, Mizuho upped their target price on LivaNova from $75.00 to $80.00 and gave the company a buy rating in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $66.20.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.